Rohto Pharmaceutical (4527) · RiskDroppedLatest Management Planning (2026-10-05): "Raised"
Risk of lower pharmaceutical shipment prices due to a review of rebate structures
First written in FY2017-Q1. 4 of 12 entries say "Advanced", first in 2026-05-13. Latest entry: 2026-10-08.
12entries
11years
8from disclosures
How it moved
Same theme, other companies
Declining pharmaceutical shipment prices and sales following a review of rebate structuresA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-10-08Advancediyakutsushinsha.com
「2031年度の業績目標は、売上高4640 億円、営業利益598億円、営業利益率12.9％、海外売上比率 56％、配当性向 40％。」
収益指標を重視する方針について、2031年度の売上高、営業利益、営業利益率、海外売上比率および配当性向の具体的な目標が新たに示された。 - FY2017DroppedAnnual reportThe current fiscal year’s earnings explanation and business and other risks do not mention lower pharmaceutical shipment prices due to a review of rebate structures.
- FY2017-Q2MaterialisedAnnual report
「The effects included lower pharmaceutical shipment prices due to a review of rebate structures.」
Lower pharmaceutical shipment prices due to a review of rebate structures continued to be cited as a factor in the decline in Japan sales for the six months ended the second quarter. - FY2017-Q1First statedAnnual report
「Lower pharmaceutical shipment prices due to a review of rebate structures」
The disclosure explicitly states that lower pharmaceutical shipment prices due to a review of rebate structures were a factor in the decline in sales in Japan.